62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer

被引：1
|
作者：
Gnant, M. [1 ,2 ,3 ]
Mlineritsch, B. [4 ]
Stoeger, H. [5 ,6 ]
Luschin-Ebengreuth, G. [5 ,6 ]
Poestlberger, S. [7 ]
Steger, G. [1 ,2 ,3 ]
Jakesz, R. [1 ,2 ,3 ]
Singer, C. [1 ,2 ,3 ]
Eidtmann, H. [8 ]
Greil, R. [4 ]
机构：
[1] Med Univ Vienna, Dept Surg, Vienna, Austria
[2] Med Univ Vienna, Dept Oncol, Vienna, Austria
[3] Med Univ Vienna, Dept Gynecol, Vienna, Austria
[4] Paracelsus Med Univ Salzburg, Dept Internal Med Oncol & Haematol 3, Salzburg, Austria
[5] Med Univ Graz, Dept Oncol, Graz, Austria
[6] Med Univ Graz, Dept Gynecol, Graz, Austria
[7] Hosp Sisters Mercy, Dept Surg, Linz, Austria
[8] Univ Schleswig Holstein, Dept Gynecol, Kiel, Germany
来源：
BONE | 2011年 / 48卷 / 01期
关键词：
D O I：
10.1016/j.bone.2010.10.045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S17 / S17
页数：1
相关论文
共 50 条
  • [1] ADJUVANT ENDOCRINE THERAPY, ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID (ZOL), IN PREMENOPAUSAL PATIENTS (PTS) WITH ENDOCRINE-RESPONSIVE EARLY BREAST CANCER (EBC): SUBGROUP ANALYSES OF ABCSG-12
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Steger, G. G.
    Jakesz, R.
    Singer, C. F.
    Eidtmann, H.
    Greil, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 79 - 79
  • [2] Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
    Gnant, Michael
    Mlineritsch, Brigitte
    Stoeger, Herbert
    Luschin-Ebengreuth, Gero
    Heck, Dietmar
    Menzel, Christian
    Jakesz, Raimund
    Seifert, Michael
    Hubalek, Michael
    Pristauz, Gunda
    Bauernhofer, Thomas
    Eidtmann, Holger
    Eiermann, Wolfgang
    Steger, Guenther
    Kwasny, Werner
    Dubsky, Peter
    Hochreiner, Gerhard
    Forsthuber, Ernst-Pius
    Fesl, Christian
    Greil, Richard
    LANCET ONCOLOGY, 2011, 12 (07): : 631 - 641
  • [3] Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Dubsky, P. C.
    Jakesz, R.
    Singer, C. F.
    Eidtmann, H.
    Greil, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor Positive Early Breast Cancer.
    Gnant, M.
    Mlineritsch, B.
    Luschin-Ebengreuth, G.
    Stoeger, H.
    Dubsky, P.
    Jakesz, R.
    Singer, C.
    Eidtmann, H.
    Fesi, C.
    Eiermann, W.
    Marth, C.
    Greil, R.
    CANCER RESEARCH, 2011, 71
  • [5] Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
    Gnant, Michael
    Mlineritsch, Brigitte
    Luschin-Ebengreuth, Gero
    Kainberger, Franz
    Kaessmann, Helmut
    Piswanger-Soelkner, Jutta Claudia
    Seifert, Michael
    Ploner, Ferdinand
    Menzel, Christian
    Dubsky, Peter
    Fitzal, Florian
    Bjelic-Radisic, Vesna
    Steger, Guenther
    Greil, Richard
    Marth, Christian
    Kubista, Ernst
    Samonigg, Hellmut
    Wohlmuth, Peter
    Mittlboeck, Martina
    Jakesz, Raimund
    LANCET ONCOLOGY, 2008, 9 (09): : 840 - 849
  • [6] The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48 and 62-Month Analyses of ABCSG-12 Suggests That the Benefits of Combining Zoledronic Acid with Adjuvant Endocrine Therapy Persist Long after Completion of Therapy
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Heck, D.
    Steger, G.
    Jakesz, R.
    Singer, C.
    Eidtmann, H.
    Greil, R.
    CANCER RESEARCH, 2010, 70
  • [7] COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY
    Delea, T. E.
    Taneja, C.
    Kaura, S.
    Chatzikou, M.
    Maiadiakis, N.
    Fagoulakis, V
    VALUE IN HEALTH, 2009, 12 (07) : A270 - A270
  • [8] Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Dubsky, P. C.
    Jakesz, R.
    Singer, C. F.
    Eidtmann, H.
    Greil, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid - new results from ABCSG-12
    Gnant, M.
    Mlineritsch, B.
    Luschin-Ebengreuth, G.
    Kainberger, F.
    Kaessmann, H.
    Piswanger-Soelkner, C.
    Seifert, M.
    Schippinger, W.
    Menzel, C.
    Dubsky, P.
    Fitzal, F.
    Steger, G.
    Greil, R.
    Marth, C.
    Kubista, E.
    Samonigg, H.
    Jakesz, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S8 - S8
  • [10] Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with early stage breast cancer based on results of the ABCSG-12 study.
    Delea, T. E.
    Taneja, C.
    Sofrygin, O.
    Kaura, S.
    Gnant, M.
    CANCER RESEARCH, 2009, 69 (02) : 190S - 191S
12345